Inhibition Of Varicella-zoster Virus Replication Research Articles

Inhibition of varicella‑zoster virus replication by an ethanol extract of Lysimachia mauritiana.

Varicella‑zoster virus (VZV), a ubiquitous human α‑herpesvirus, is the causative agent of chickenpox and shingles. In the present study, we investigated the antiviral activity of a 70% ethanol extract of Lysimachiamauritiana (LME) against VZV. LME strongly interfered with the replication of both laboratory and clinical strains of VZV without affecting the viability of MRC‑5 cells. Moreover, LME treatment suppressed the expression of an essential viral transactivator, immediate‑early 62protein (IE62), in addition to other lytic genes in the later phases of viral replication. The finding that LME exerts potent inhibitory effects on VZV gene expression and replication supports its potential utility as a therapeutic anti‑viral agent.

Resveratrol inhibition of varicella-zoster virus replication in vitro

Resveratrol was found to inhibit varicella-zoster virus (VZV) replication in a dose-dependent and reversible manner. This decrease in virus production in the presence of resveratrol was not caused by direct inactivation of VZV or inhibition of virus attachment to MRC-5 cells. The drug effectively limited VZV replication if added during the first 30 h of infection. Western blot analysis and real-time RT-PCR studies demonstrated that protein and mRNA levels of IE62, an essential immediate early viral protein, were reduced when compared to controls. These results demonstrate that VZV replication is adversely affected by resveratrol which is negatively impacting IE62 synthesis.

Role of the protein kinase PKR in the inhibition of varicella-zoster virus replication by beta interferon and gamma interferon

Varicella-zoster virus (VZV) is sensitive to type I and type II interferons (IFNs), which mediate antiviral effects. In this study, it was demonstrated that IFN-beta and IFN-gamma inhibited the replication of VZV in vitro. Although IFN-beta was more effective than IFN-gamma, the level of inhibition of VZV replication achieved by the combination of both IFNs was more than additive and it was concluded that these two cytokines acted synergistically. Expression of the IFN-induced, double-stranded RNA-activated protein kinase PKR and its phosphorylation level were not modulated strongly during ongoing replication of VZV. However, in the presence of IFN-beta, but not IFN-gamma, PKR expression and its phosphorylation were increased, explaining in part the inhibition of virus replication by IFNs. The expression of herpes simplex virus Us11, a viral protein with several functions, including prevention of PKR activation, strongly increased the level of VZV replication.

Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo[2,3-d]pyrimidine nucleoside analogues.

The bicyclic furo[2,3-d]pyrimidine nucleoside analogues represent an entirely new class of fused furopyrimidine derivatives with unprecedented selectivity for varicella-zoster virus (VZV). From extensive structure-activity relationship (SAR) studies, the 6-(p-alkylphenyl)substituted furopyrimidine derivatives Cf 1742 and Cf 1743 emerged as the most potent inhibitors of VZV replication: they were found to inhibit both laboratory VZV strains and clinical VZV isolates at subnanomolar concentrations, while not being toxic to the host cells at 100,000-fold higher concentrations. Although the precise mechanism of action of these compounds remains to be elucidated, it is clear that for their antiviral activity they depend on phosphorylation by the VZV-encoded thymidine kinase. The furo[2,3-d]pyrimidine nucleoside analogues are not susceptible to degradation by human or bacterial thymidine phosphorylase, which may otherwise release the free aglycone. Also, the latter is not inhibitory to dihydropyrimidine dehydrogenase, an enzyme involved in the degradation of thymine, uracil, and the anticancer agent 5-fluorouracil. Further development of the furo[2,3-d]pyrimidine nucleoside analogues as new therapeutic modalities for the treatment of VZV infections (i.e., varicella and herpes zoster) seems highly justified.

Synergistic Anti-Varicella-Zoster Virus Activity of Interferon-ά2a and Acyclovir in Corneal Cells

Human corneal stromal (HCS) cells in cultures established from donor corneas can serve as host cells for replication of varicella-zoster virus (VZV). Comparative infectious centers assays suggest that HCS cells are more restrictive hosts than MRC-5 cells, a line of human embryonic lung fibroblasts, commonly used for VZV isolation. VZV propagated in MRC-5 cells was infectious for both MRC-5 and HCS cells, but titers in HCS were one fifth of those in MRC-5 cells. Inhibition of VZV replication in HCS cells by acyclovir (ACV), recombinant human interferon-alpha 2a (IFN-alpha 2a), or the combination of these two antivirals was detected by both an infectious centers-plaque-reduction assay and an ELISA method using monoclonal anti-VZV antibody. In the infectious centers-plaque-reduction assay combinations of ACV with IFN-alpha 2a showed synergistic anti-VZV activity. VZV protein synthesis, as detected by the ELISA, was a less sensitive measure of the antiviral effects producing an ED50 value of 50 microM for ACV, five to ten times the ED50 determined in the plaque reduction assay. In the ELISA, high titers of IFN-alpha 2a (2000 IU/ml) decreased virus antigen expression only slightly, while combinations of ACV and IFN-alpha 2a were synergistic in their detected anti-VZV activity. These data document the replication of VZV in HCS cells and demonstrate that VZV is sensitive to the synergistic antiviral action of combinations of IFN-alpha 2a and ACV.

Current experience with antiviral therapy for acute herpes zoster.

Inhibition of varicella-zoster virus replication during acute herpes zoster would, theoretically, accelerate cutaneous healing and reduce the pain, both acute and chronic, associated with shingles. Early antiviral drugs were of limited efficacy, excessively toxic, or needed to be given parenterally, and were unsuitable for use in immunocompetent individuals. Acyclovir was a significant advance and remains the antiviral drug of choice for herpes zoster. There is ample evidence for its efficacy in acute illness, but its ability to influence post-herpetic neuralgia is controversial. This review also discusses the role of adjunctive therapy with steroids in acute shingles.

Inhibition of varicella-zoster virus replication by an inhibitor of protein myristoylation

Inhibitors of myristoylation and analogues of myristic acid inhibit the replication of some retroviruses including human immunodeficiency virus, but no studies with other virus families have been reported. We have shown that replication of varicella-zoster virus (VZV) in tissue is inhibited by DL-2-hydroxymyristic acid at concentrations similar to those required for inhibition with acyclovir. Protein synthesis is not inhibited, but protein myristoylation is non-specifically reduced. Despite this lack of specificity, DL-2-hydroxymyristic acid inhibits VZV replication without apparent cytotoxicity. This is in agreement with our earlier suggestion that non-specific inhibitors of myristoylation could have antiviral effects without toxicity to cells due to the stability of cellular myristoylproteins. This supports suggestions that myristoylation inhibitors have potential as antiviral drugs against the many viruses that produce myristoylproteins.

Inhibiting effect of (RS)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine on varicella-zoster virus replication in cell culture.

The activity and mode of action of the new nucleoside analog (RS)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (2HM-HBG) against varicella-zoster virus (VZV) were determined. In cell culture, replication of different strains of VZV was inhibited to 50% by 0.4 to 0.7 microM 2HM-HBG, while 685 microM was required to inhibit 50% of the DNA synthesis in uninfected human lung fibroblasts. A thymidine kinase-negative VZV strain was not inhibited by 100 microM 2HM-HBG. Inhibition of VZV replication was not reversible after 7 to 14 days of incubation, depending on the multiplicity of VZV. 2HM-HBG was shown to be selectively phosphorylated by purified VZV thymidine kinase, with an inhibition constant of 32.5 microM. The antiviral activity of 2HM-HBG in cell culture was decreased by the addition of deoxythymidine and deoxycytidine but not by other ribo- or deoxyribonucleosides.